Iradimed Co (IRMD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Iradimed Co stock (IRMD) is currently trading at $101.78. Iradimed Co PE ratio is 56.86. Iradimed Co PS ratio (Price-to-Sales) is 15.17. Analyst consensus price target for IRMD is $120.00. WallStSmart rates IRMD as Hold.
- IRMD PE ratio analysis and historical PE chart
- IRMD PS ratio (Price-to-Sales) history and trend
- IRMD intrinsic value — DCF, Graham Number, EPV models
- IRMD stock price prediction 2025 2026 2027 2028 2029 2030
- IRMD fair value vs current price
- IRMD insider transactions and insider buying
- Is IRMD undervalued or overvalued?
- Iradimed Co financial analysis — revenue, earnings, cash flow
- IRMD Piotroski F-Score and Altman Z-Score
- IRMD analyst price target and Smart Rating
Iradimed Co
📊 No data available
Try selecting a different time range
IRMD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Iradimed Co (IRMD)
IRMD trades 27% above its Graham fair value of $81.34, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Iradimed Co (IRMD) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, eps growth. Concerns around peg ratio and price/sales. Fundamentals are solid but monitor weak areas for improvement.
Iradimed Co (IRMD) Key Strengths (5)
Keeps $31 of every $100 in revenue after operating costs
Keeps $27 of every $100 in revenue as net profit
Every $100 of equity generates $25 in profit
Strong earnings growth at 24.80% per year
60.33% held by institutions, strong professional interest
Supporting Valuation Data
Iradimed Co (IRMD) Areas to Watch (5)
Very expensive relative to growth, significant premium
Very expensive at 15.2x annual revenue
Very expensive at 13.4x book value
Small-cap company with higher risk but more growth potential
Solid revenue growth at 17.00% per year
Supporting Valuation Data
Iradimed Co (IRMD) Detailed Analysis Report
Overall Assessment
This company scores 60/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 3.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Profit Margin, Return on Equity. Profitability is solid with Return on Equity at 24.80%, Operating Margin at 31.30%, Profit Margin at 26.80%. Growth metrics are encouraging with EPS Growth at 24.80%.
The Bear Case
The primary concerns are PEG Ratio, Price/Sales, Price/Book. Some valuation metrics including PEG Ratio (4.46), Price/Sales (15.17), Price/Book (13.42) suggest expensive pricing. Growth concerns include Revenue Growth at 17.00%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 24.80% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 17.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Operating Margin, Profit Margin) and negatives (PEG Ratio, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IRMD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IRMD's Price-to-Sales ratio of 15.17x trades at a 46% premium to its historical average of 10.39x (87th percentile). The current valuation is 41% below its historical high of 25.64x set in Nov 2015, and 370% above its historical low of 3.23x in Feb 2017. Over the past 12 months, the PS ratio has expanded from ~9.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Iradimed Co (IRMD) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Iradimed Co is a strong growth company balancing expansion with improving profitability. Revenue reached 84M with 17% growth year-over-year. Profit margins are strong at 26.8%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 2480.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 26.8% and operating margin of 31.3% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Valuation compression risk at a P/E of 56.9x. Any growth miss could trigger a sharp correction.
Dividend sustainability with a current yield of 71.0%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Iradimed Co.
Bottom Line
Iradimed Co offers an attractive blend of growth (17% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Iradimed Co(IRMD)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.